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Objective: The objective of this study was to evaluate the intestinal barrier function in
leukemia patients before the start of the chemotherapy with an intestinal permeability test
using lactulose and mannitol as markers.
Methods: The study enrolled 20 patients diagnosed with leukemia (acute and chronic). Ten
healthy volunteers were also submitted to the test as a control group.
Results: The median lactulose/mannitol ratio was 0.019 for the Leukemia Patient Group,
whereas in healthy controls the median was 0.009 (p-value = 0.244). The median lactu-
lose/mannitol ratio in acute leukemia patients was 0.034 giving a p-value of 0.069 when
compared to healthy controls. This same comparison was made between acute myeloid
leukemia patients and healthy controls with a p-value of 0.149. There was no signiﬁcant
difference in the intestinal permeability between acute and chronic leukemia patients (p-
value = 0.098).
Conclusion: The intestinal barrier function measured using the intestinal permeability test
was  similar in leukemic patients overall and healthy controls, but a tendency toward a
different pattern was found in the intestinal barrier function of acute leukemia patients.©  2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.ntroductioneukemias are diseases characterized by neoplastic prolifera-
ion that affect the bone marrow and inhibit hematopoiesis,
ausing abnormalities in peripheral blood and sometimes
nﬁltrating non-hematopoietic tissues.1 The gastrointestinal
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eserved.tract may be affected, either by leukemic inﬁltration or
by therapy-associated complications.2 Leukemia cell inﬁl-
tration may occur in any segment of the gastrointestinal
tract and may cause stomatitis, gingivitis or gum hypertro-), Av. Professor Alfredo Balena, 190, Santa Eﬁgênia, 30130-100 Belo
phy, oropharyngeal dysphagia and the formation of masses
in the esophagus, stomach, small intestines and colon
which, in turn, are associated to obstruction, hemorrhage,
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
oter.410  rev bras hematol hem
intussusception or enterocolitis. In the small gut, leukemia
inﬁltration may reduce the integrity of the mucosal barrier,
allowing antigen permeation and reduction of absorption
area.3 The involvement of this organ is most often seen in
acute myeloid leukemia (AML).2,4
These changes in the intestinal barrier can be studied
through intestinal permeability; the most commonly used
markers are sugars such as lactulose and mannitol, since they
do not require the use of radioactive techniques.5–7
The intestinal permeability test (TL/M) is a useful method
to evaluate the integrity of the intestinal mucosa in any con-
dition which would cause the loosening of tight junctions,
including those affecting the small gut, such as in Crohn’s and
celiac diseases and diseases which are associated to a sec-
ondary inﬁltration of this organ such as leukemia.8 By using
this method, it is also possible to study mucositis secondary
to the use of chemotherapeutic agents.9 Changes in intesti-
nal permeability, detected before chemotherapy in leukemia
patients and their eventual clinical consequences, such as
a greater antigen permeation, may contribute to elucidate
pathophysiological mechanisms involved in the context of the
disease and its therapy, and possibly, come up with more  spe-
ciﬁc solutions to problems related to these changes, such as
infection and graft versus host disease (in the case of marrow
transplantation).
Objective
The aim of the study was to evaluate the intestinal barrier
function in leukemic patients prior to chemotherapy, by test-
ing intestinal permeability by the determination of urinary
lactulose and mannitol concentrations by high performance
liquid chromatography (HPLC).
Methods
Patients
Between April 2010 and September 2011, this study enrolled
20 patients aged 18 years or above, of both genders, with
initial diagnoses of AML, chronic myeloid leukemia (CML),
acute lymphoblastic leukemia (ALL) and chronic lympho-
cytic leukemia (CLL) admitted in the Hematology Outpatient
Clinic and Emergency Department of the Hospital das Clínicas
da Universidade Federal de Minas Gerais, before undergoing
chemotherapy induction. The use of the TL/M did not result
in any change in medical management. Ten over 18-year-
old healthy volunteers, of both genders, also underwent the
TL/M.
Patients diagnosed with bowel disease, cirrhosis, conges-
tive heart failure, nephrotic syndrome, thyroid diseases or
diabetes mellitus, diseases that could interfere with absorp-
tion or ﬂow of water and solutes and/or gastrointestinal
motility were excluded from the research as were patients who
drank alcoholic beverages within three days and took non-
steroidal anti-inﬂammatory drugs (NSAIDs) within seven days
prior to urine collection. 2 0 1 4;3  6(6):409–413
Methods
The study was approved by the Research Ethics Commit-
tee of the Universidade Federal de Minas Gerais (ETIC
0079.0.203.000-11). All participants signed an informed con-
sent term before the study was initiated.
Diagnosis of leukemia was conﬁrmed by myelogram, bone
marrow biopsy and cytogenetic or genetic studies when nec-
essary.
In order to perform the TL/M, patients fasted for eight hours.
Subsequently, they were instructed to eliminate any resid-
ual urine and a 120 mL iso-osmolar solution containing 6.25 g
of lactulose (95%) (Sigma–Aldrich, Missouri, USA) and 3.0 g
of mannitol (PA) (Sigma–Aldrich, Missouri, USA) diluted in
water was given. Fasting was maintained for the following
two hours. All urine volume was collected during a period
of ﬁve hours. Subsequently, the urine was homogenized and
the total volume was recorded. Aliquots of 50 mL  were stored
in labeled in sealed ﬂasks after adding 10 mg of thimerosal
(Synth, Diadema, Brazil) to inhibit bacterial growth. Samples
were ﬁltered using a millipore ﬁlter (0.22 m)  (Millipore, Biller-
ica, USA), and the ion-exchange resin and the material were
stored in properly labeled cryotubes at −20 ◦C.
The mannitol and lactulose concentrations were measured
in the urine using HPLC equipment (Schimadzu®, Japan) com-
prising an injection pump, an autoinjector, a controller with
software that allows readings to be interpreted at a work-
station, and a refractive index gauge. Fifty microliters of
urine were introduced after thawing using the autoinjector. To
achieve better separation from other substances in the urine,
lactulose and mannitol were read using two different columns
utilizing two distinct mobile phases. A Phenomenex H+ col-
umn (Phenomenex, USA) with a mobile phase of pure milli-Q
sonicated water at a ﬂow of 0.6 mL/min was used to separate
the mannitol and a Supelcogel NH2 column (Sigma Aldrich,
Bellefonte, USA) with a mobile phase of a solution of ace-
tonitrile and milli-Q sonicated water (ratio of 75/25) with a
ﬂow of 1.0 mL/min was employed to separate the lactulose. A
Supelcogel H+ precolumn (Sigma Aldrich, Bellefonte, USA) was
the same for both readings. Different amplitudes of the waves
generated by the solution containing lactulose and mannitol
were captured at the workstation, generating graphs in the
form of curves, which were then recorded. Analyses were car-
ried out at room temperature.
To test reproducibility and to standardize measurements,
solutions of lactulose were prepared at known concentrations
of 0.1 g/L, 0.2 g/L, 0.4 g/L and 0.8 g/L, as were solutions of man-
nitol at concentrations of 0.625 g/L, 1.25 g/L and 2.5 g/L and a
simple linear regression was performed in order to obtain a
straight line equation for both.
By correcting for the urine volume, the amount excreted
was obtained for lactulose and mannitol, which was then
divided by the amount ingested to calculate an excreted per-
centage of each sugar. The percentage of lactulose was divided
by the percentage of mannitol in order to obtain the lactu-
lose/mannitol excretion ratio (TL/M).Clinical and laboratory variables were recorded. Statisti-
cal analyses were performed using the Statistics Program
for Social Sciences (SPSS version 18.0). Student’s t test was
employed to compare independent sample means and when
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Table 1 – Intestinal permeability test between leukemia patients and healthy volunteers.
Mean % Standard deviation Median % (range) p-Value
Percentage lactulose
Healthy volunteers 0.14 0.14 0.09 (0.02–0.48) 0.311
Leukemia patients 0.27 0.26 0.23 (0.01–0.97)
Percentage mannitol
Healthy volunteers 11.44 4.34 11.60 (4.70–18.0) 0.403
Leukemia patients 9.78 5.37 10.55 (0.60–21.70)
TL/M
Healthy volunteers 0.012 0.010 0.009 (0.001–0.027) 0.244
Leukemia patients 0.061 0.115 0.019 (0.001–0.488)
TL/M: lactulose/mannitol ratio.
Table 2 – Intestinal permeability test between acute leukemia patients and healthy volunteers.
n Mean % Standard deviation Median % (range) p-Value
Percentage lactulose
Healthy volunteers 10 0.14 0.14 0.09 (0.02–0.48) 0.170
Leukemia patients 16 0.31 0.27 0.26 (0.01–0.97)
Percentage mannitol
Healthy volunteers 10 11.44 4.34 11.60 (4.70–18.0) 0.215
Acute leukemia patients 16 8.97 5.07 8.75 (0.60–16.80)
TL/M
Healthy volunteers 10 0.012 0.010 0.009 (0.001–0.027) 0.069
Acute leukemia patients 16 0.074 0.126 0.034 (0.001–0.483)
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TTL/M: lactulose/mannitol ratio.
ata did not have a Gaussian distribution, the Mann–Whitney
est was used to compare medians. An alpha error of 5%
p-value < 0.05) was considered the threshold for statistical sig-
iﬁcance.
esults
nitially, 26 patients with suspected diagnoses of leukemia
efore the beginning of the treatment were invited to take part
n the study. After the results of the conﬁrmatory tests, two
atients were excluded as they were diagnosed with myeloﬁ-
rosis. Four other patients refused to take part in the research.
hus, 20 patients, nine males (45%) and 11 females (55%), with
Table 3 – Intestinal permeability test between acute myeloid leu
n Mean % Standa
Percentage lactulose
Healthy volunteers 10 0.14 
AML patients 11 0.33 
Percentage mannitol
Healthy volunteers 10 11.44 
AML patients 11 9.66 
TL/M
Healthy volunteers 10 0.012 
AML patients 11 0.077 
TL/M: lactulose/mannitol ratio.conﬁrmed diagnosis of leukemia participated in the research.
Ages ranged from 18 to 81 years, with a mean of 47.2 years.
Sixteen patients (80%) had acute (11 AML  and ﬁve ALL) and
four (20%) had chronic leukemia (three CML  and one CLL).
Gastrointestinal manifestations such as nauseas, vomits,
abdominal pain or discomfort and diarrhea were present in
eight (40%) patients, seven with AML and one with CML. Fever
was present in nine (45%) patients, six with AML, one with ALL
and two with CML.
The mean TL/M in leukemia patients, calculated from the
relationship between lactulose and mannitol excretion rates,
was 0.061 ± 0.115 and the median was 0.019 (0.001 to 0.483) and
the mean TL/M in healthy volunteers was 0.012 ± 0.010 and the
median was 0.009 (0.001–0.027) (Table 1).
kemia patients and healthy volunteers.
rd deviation Median % (range) p-Value
0.14 0.09 (0.02–0.48) 0.204
0.30 0.29 (0.01–0.97)
4.34 11.60 (4.70–18.0) 0.397
4.99 9.90 (0.60–16.80)
0.010 0.009 (0.001–0.027) 0.149
0.138 0.042 (0.001–0.483)
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Table 4 – Intestinal permeability test between acute leukemia patients and chronic leukemia patients.
n Mean % Standard deviation Median % (range) p-Value
Percentage lactulose
Acute leukemia 16 0.30 0.27 0.26 (0.01–0.97) 0.275
Chronic leukemia 4 0.14 0.19 0.07 (0.01–0.42)
Percentage mannitol
Acute leukemia 16 8.97 5.07 8.75 (0.60–16.80) 0.187
Chronic leukemia 4 13.0 6.09 11.40 (7.50–21.70)
TL/M
Acute leukemia 16 0.074 0.126 0.034 (0.001–0.483) 0.098
Chronic leukemia 4 0.008 0.008 0.007 (0.001–0.019)
TL/M: lactulose/mannitol ratio.
Table 5 – Intestinal permeability test between acute myeloid leukemia patients and chronic leukemia patients.
n Mean % Standard deviation Median % (range) p-Value
Percentage lactulose
AML patients 11 0.33 0.30 0.29 (0.01–0.97) 0.269
Chronic leukemia 4 0.14 0.19 0.07 (0.01–0.42)
Percentage mannitol
AML patients 11 9.66 4.99 9.90 (0.60–16.80) 0.297
Chronic leukemia 4 13.0 6.09 11.40 (7.50–21.70)
TL/M
AML patients 11 0.077 0.139 0.042  (0.001–0.483) 0.192
Chronic leukemia 4 0.008 0.008 0.007 (0.001–0.019)TL/M: lactulose/mannitol ratio.
Comparisons of the TL/M between acute leukemia patients
and healthy volunteers, and between AML patients and
healthy volunteers were also performed. In patients with
acute leukemia, the median TL/M was 0.034 (0.001–0.483) giv-
ing a p-value of 0.069 compared to the median of healthy
volunteers (Table 2). On comparing the median TL/M of AML
patients (0.042) and the median of healthy volunteers (0.009)
the p-value was 0.149 (Table 3).
The TL/M was also compared between acute leukemia
and chronic leukemia patients. The median TL/M for acute
leukemia patients was 0.034, whereas it was 0.007 for chronic
leukemia patients (p-values = 0.098) (Table 4). The median TL/M
was 0.042 and 0.007 for AML  and chronic leukemia patients,
respectively (p-value = 0.192) (Table 5).
Leukemia patients with gastrointestinal symptoms or fever
did not present different TL/M values from the leukemia sub-
groups without these manifestations.
Discussion
In this study, leukemia patients had higher median TL/M values
(0.019) when compared to the median of healthy volunteers
(0.009), however, the difference was not statistically signiﬁcant
(p-value = 0.244). This ﬁnding may be explained by the small
sample size and by the wide range of results found in leukemia
patients (0.001–0.483). However, in this sample, some leukemia
patients did not have changes in the function of the intesti-
nal barrier, which is perfectly understandable, since not all
leukemia patients have inﬁltration of the small intestinal wall.
It is assumed that there are differences between subgroups ofleukemia and this may involve a greater or lesser number of
complications, primarily those associated to sepsis resulting
from greater permeation of antigens in patients with higher
TL/M values.10 In 1998, Sundström et al.11 compared intesti-
nal permeability in AML  patients before chemotherapy with
results obtained from health volunteers and observed higher
values in the ﬁrst group, however, some patients also had
their intestinal barrier function preserved.11 In this study, the
median of the TL/M of AML  patients before beginning the treat-
ment (0.043) was signiﬁcantly higher (p-value = 0.02) when
compared to the median of healthy volunteers (0.025). Bow
and Meddings9 also evaluated the intestinal barrier function
in AML patients before the induction of chemotherapy and
found that the TL/M was also higher before beginning the ther-
apy (0.03) compared to the mean reference score mentioned
by the authors (TL/M < 0.028).9
The median TL/M of acute leukemia patients was 0.034
whereas it was 0.009 in healthy volunteers (p-value = 0.069).
Although the difference was not statistically signiﬁcant, it is
possible that there is a tendency for the intestinal barrier to
be different between the two  groups. This comparison was
also performed exclusively among AML patients. The median
TL/M in AML patients was also higher (0.042) compared to
the control group (0.009), however, the p-value was 0.149.
When analyzing these results, it was again found that results
from AML patients varied considerably. In these patients, the
minimum and the maximum values were 0.001 and 0.483,
respectively. In addition, the results overlapped, i.e. some AML
patients also initially had an intestinal barrier function similar
to that of the healthy volunteers.
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11. Sundström GM, Wahlin A, Nordin-Anderson I, Suhr OB.
Intestinal permeability in patients with acute myeloid
leukemia. Eur J Haematol. 1998;61(4):250–4.rev bras hematol hemot
AMLs are more  associated to intestinal injury than other
ypes of leukemia.2,4 In this study, the median TL/M of acute
eukemia patients was 0.034. When compared to the median
f the group of chronic leukemia patients (median TL/M = 0.007;
ange: 0.001–0.019), the p-value was 0.098. However, one can
lso infer that there is a tendency to behave differently
etween the two groups of patients. All TL/M results in chronic
eukemia were within the range of the healthy controls. The
edian TL/M in AML  patients was even higher (0.042), but
ot signiﬁcantly different compared to the results of chronic
eukemia patients (p-value = 0.192); this may also have been
nﬂuenced by the wide range of results of the ﬁrst group.
Although there are few studies in the literature analyzing
ntestinal changes associated to leukemias using the TL/M in
dults before chemotherapy, it is possible to suppose that a
ubgroup of acute leukemia patients may have higher val-
es compared to healthy individuals. Although most studies
ave aimed to show the damage caused by chemotherapy,
he intestinal barrier function is likely to have already been
mpaired and so further changes may add to the lesions
aused by chemotherapeutic agents. Evidence of changes
n intestinal permeability indicating changes of the intesti-
al mucosal barrier in a subset of leukemia patients before
hemotherapy may correlate with prognosis and so future
nvestigations should try to identify interventions to minimize
hese effects.
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